PMID- 24004561
OWN - NLM
STAT- MEDLINE
DCOM- 20140630
LR  - 20211021
IS  - 1746-6148 (Electronic)
IS  - 1746-6148 (Linking)
VI  - 9
DP  - 2013 Sep 3
TI  - Concurrent short-term use of prednisolone with cyclosporine A accelerates 
      pruritus reduction and improvement in clinical scoring in dogs with atopic 
      dermatitis.
PG  - 173
LID - 10.1186/1746-6148-9-173 [doi]
AB  - BACKGROUND: A randomized, unmasked, multicenter study was conducted to evaluate 
      the rate of pruritus reduction and improvement in clinical scoring by 
      cyclosporine A (5 mg/kg orally, once daily for 28 days) either alone (n = 25 
      dogs) or with concurrent prednisolone (1 mg/kg once daily for 7 days, followed by 
      alternate dosing for 14 days; n = 23 dogs) for the treatment of atopic dermatitis 
      in dogs. Dogs were included in the study after exclusion of other causes of 
      pruritic dermatitis, and were assessed by dermatologists on days 0, 14 +/- 1 and 28 
      +/- 2. Assessments included: general physical examination, CADESI-03 lesion 
      scoring, overall clinical response, evaluation of adverse events (AEs), body 
      weight and clinical pathology (hematology, clinical chemistry and urinalysis). 
      Owner assessments, including pruritus (visual analogue scale, VAS) and overall 
      assessment of response were conducted every 3-4 days, either during visits to the 
      clinic or at home. Owners reported AEs to the investigator throughout the study. 
      RESULTS: By day 28 +/- 2 both treatment groups resulted in a significant 
      improvement of the atopic dermatitis. Both investigators and owners agreed that 
      concurrent therapy resulted in a quicker improvement of the dogs 'overall' skin 
      condition and of pruritus (significant reduction of pruritus by day 3-4, 72.8% 
      improvement by day 14 +/- 1), when compared to cyclosporine A alone (significant 
      reduction of pruritus by day 7-8, 24.7% improvement by day 14 +/- 1). CADESI-03 
      scores significantly improved in both groups by day 14 +/- 1 onwards, and there 
      were no significant differences in the scores between treatment groups at any 
      time points. A total of 56 AEs (cyclosporine A alone = 34; concurrent therapy = 
      22) were reported in 33 dogs. No dogs died or stopped treatment due to an AE. The 
      most commonly reported AEs in the cyclosporine A group were associated with the 
      digestive tract, whilst systemic disorders were reported more frequently observed 
      following concurrent therapy. Evaluation of body weight change and clinical 
      pathology indices showed no overall clinically significant abnormalities. 
      CONCLUSIONS: In dogs with atopic dermatitis, a short initiating course of 
      prednisolone expedited the efficacy of cyclosporine A in resolving pruritus and 
      associated clinical signs. The observed adverse events were consistent with those 
      expected for the individual veterinary medicinal products.
FAU - Dip, Ramiro
AU  - Dip R
AD  - Novartis Animal Health Inc,, Schwarzwaldallee 215, CH-4058 Basel, Switzerland. 
      ramiro.dip@novartis.com.
FAU - Carmichael, James
AU  - Carmichael J
FAU - Letellier, Ingrid
AU  - Letellier I
FAU - Strehlau, Guenther
AU  - Strehlau G
FAU - Roberts, Elizabeth
AU  - Roberts E
FAU - Bensignor, Emmanuel
AU  - Bensignor E
FAU - Rosenkrantz, Wayne
AU  - Rosenkrantz W
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130903
PL  - England
TA  - BMC Vet Res
JT  - BMC veterinary research
JID - 101249759
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - 9PHQ9Y1OLM (Prednisolone)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/administration & dosage/adverse effects/therapeutic use
MH  - Cyclosporine/administration & dosage/adverse effects/*therapeutic use
MH  - Dermatitis, Atopic/drug therapy/*veterinary
MH  - Dog Diseases/*drug therapy
MH  - Dogs
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Immunosuppressive Agents/administration & dosage/adverse effects/therapeutic use
MH  - Male
MH  - Prednisolone/administration & dosage/adverse effects/*therapeutic use
MH  - Pruritus/*drug therapy
PMC - PMC3847128
EDAT- 2013/09/06 06:00
MHDA- 2014/07/01 06:00
PMCR- 2013/09/03
CRDT- 2013/09/06 06:00
PHST- 2013/05/14 00:00 [received]
PHST- 2013/08/29 00:00 [accepted]
PHST- 2013/09/06 06:00 [entrez]
PHST- 2013/09/06 06:00 [pubmed]
PHST- 2014/07/01 06:00 [medline]
PHST- 2013/09/03 00:00 [pmc-release]
AID - 1746-6148-9-173 [pii]
AID - 10.1186/1746-6148-9-173 [doi]
PST - epublish
SO  - BMC Vet Res. 2013 Sep 3;9:173. doi: 10.1186/1746-6148-9-173.